Daniel Shapiro, MD, FACS, discusses how emerging biomarker strategies and evolving combination therapies are reshaping risk stratification and treatment decision-making in kidney cancer.
Daniel D. Shapiro, MD, FACS
Advertisement
Shapiro is an assistant professor of urology at the University of Wisconsin School of Medicine and Public Health in Madison.
Articles by Daniel D. Shapiro, MD, FACS
"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
FDA approves tebipenem pivoxil for complicated urinary tract infections
4
Retrospective study suggests differences in OAB therapy persistence among older adults
5